Teleios Health Review
Best for: Buyers comparison-shopping among cash-pay compounded-semaglutide ($99/mo floor) and compounded-tirzepatide ($139/mo floor) telehealth platforms and willing to contact the operator directly to confirm state availability, pharmacy partner, lab requirements, and refund policy before purchase.
Teleios Health (teleioshealth.care; canonical teleios.health) is a physician-led, cash-pay GLP-1 weight-loss telehealth platform marketing compounded semaglutide injection from $99/mo and compounded tirzepatide injection from $139/mo. Per its homepage and Open Graph meta: physicians (MDs/DOs) prescribe; medication is delivered direct-to-door; the platform claims 100% online intake. Specific dose tiers, compounding-pharmacy partner, state availability, BMI eligibility, lab requirements, refund/cancellation policy, named medical director, and corporate founding date are NOT publicly listed on the static site (single-page React app served via Google Frontend; body content rendered client-side and not present in raw HTML). The platform integrates the Myosin advertising-analytics platform (ops.myosin.io capi snippet) and Google Tag Manager (GTM-M5PW87MF) for paid-acquisition attribution — a common ad-spend stack among newer compounded-GLP-1 entrants. LOW-confidence diagnostic listing pending live operator verification.
Low confidence · Last verified 2026-05-28 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Teleios Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Teleios Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| starting tier | compounded injection | $99 |
| starting tier | compounded injection | $139 |
✓ Pros
- •Lowest published compounded-semaglutide floor price tier in the cash-pay segment at $99/mo (per Open Graph + page-title meta; floor only — maintenance dose pricing not surfaced publicly)
- •Compounded-tirzepatide also offered at a competitive $139/mo floor
- •Explicitly markets physician (MD/DO) prescribing rather than NP-only model
- •Clean meta-tag and Open Graph implementation — the operator clearly invests in marketing attribution and SEO basics
✗ Cons
- •Single-page React app: state availability, pharmacy partner, dose-tier pricing ladder, lab requirements, refund/cancellation policy, and BMI eligibility are NOT visible in static HTML and could not be live-verified
- •No named medical director, founder, physician, or corporate entity disclosed in the static site meta
- •Year founded NOT_VERIFIED — newer entrants in this floor-price band warrant elevated KYC scrutiny
- •No LegitScript / NABP / SOC 2 trust-signal claim surfaced in the static markup reviewed
- •Ad-tech stack (Myosin CAPI + Google Tag Manager) is consistent with a paid-acquisition-led growth model — not a knock by itself, but worth pairing with elevated diligence on the clinical layer before purchase
- •Floor-only pricing transparency: 'from $99/mo' / 'from $139/mo' framing does not surface the maintenance-dose ceiling that buyers will actually pay
Ready to start with Teleios Health?
Starting at $99/month. See current pricing and start your free consultation.
Sources & methodology
Our Teleios Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Teleios Health
Belle Health
Best for: Cost-sensitive patients comfortable with the Feb-2026 FDA warning, wanting flat-rate pricing and dietitian-included support
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-oriented patients who want compounded GLP-1 alongside hormone and performance programs from a 25-year-old established brand
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Teleios Health?
Starting at $99/month. See current pricing and start your free consultation.